Novo Holdings Acquires The Ritedose Corporation

Pfizer Acquires Biohaven Pharmaceutical Holding Company Ltd.

October 3, 2022

Pharmaceuticals

Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. for approximately $11.6 billion (at $148.50 per share), bringing the migraine therapy NURTEC ODT (rimegepant), the zavegepant NDA program, and a CGRP-focused pipeline into Pfizer's Internal Medicine portfolio. Prior to closing, Biohaven spun off its non-CGRP assets into a separate publicly traded company, Biohaven Ltd., which Pfizer received a small pro rata stake in.

Roche Acquires Poseida Therapeutics

November 28, 2024

Biotechnology

Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.

Viatris Acquires Aculys Pharma to Secure CNS Assets and Japan/APAC Rights

October 15, 2025

Pharmaceuticals

Viatris Inc. has acquired clinical-stage Aculys Pharma, Inc., obtaining exclusive development and commercialization rights in Japan for pitolisant and rights in Japan and select Asia‑Pacific markets for Spydia (diazepam) nasal spray. The deal includes an upfront payment to Aculys shareholders with additional milestone and royalty payments, and is intended to strengthen Viatris' presence and CNS capabilities in Japan.

SP Industries (Harbour Group) Acquires i-Dositecno

October 31, 2019

Manufacturing

SP Industries, a Harbour Group company, acquired Irta Dosificacio I Technologia S.L. (i-Dositecno), a Spain-based provider of sterile liquid filling lines for pharmaceutical, cosmetic and ophthalmic applications. The acquisition (terms undisclosed) expands SP Industries' fill-finish product portfolio and adds i-Dositecno's European and Asian footprint and engineering/service capabilities to better serve global customers.

iMD Companies, Inc. Acquires Riize, LLC

August 29, 2024

Healthcare Services

iMD Companies, Inc. (OTC: ICBU) has completed the acquisition of Riize, LLC, an online telemedicine and pharmacy services provider focused on sexual health and weight loss products. iMD said it will provide resources to scale Riize's product portfolio and subscriber base as part of its healthcare-focused holding company strategy.

Bristol Myers Squibb Acquires RayzeBio for Approximately $4.1 Billion

December 26, 2023

Biotechnology

Bristol Myers Squibb will acquire radiopharmaceutical developer RayzeBio in an all-cash tender offer of $62.50 per share, valuing RayzeBio at approximately $4.1 billion (about $3.6 billion net of cash). The acquisition brings RayzeBio's actinium-based radiopharmaceutical platform, a Phase 3 lead program (RYZ101) and in-house radiopharmaceutical manufacturing capabilities into Bristol Myers Squibb's oncology franchise to accelerate development and commercialization of targeted radiopharmaceutical therapeutics.